Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is a Oxazolidinone presented as an injectable solution for Intravenous use. It treats Gram‑positive bacterial infections, including MRSA, in hospitalized patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid Kabi is an Oxazolidinone antibiotic indicated for serious Gram‑positive infections.

- Skin and soft tissue infections: effective against cellulitis and wound infections caused by susceptible Gram‑positive bacteria. - Community‑acquired and nosocomial pneumonia: used to treat pneumonia caused by linezolid‑susceptible organisms. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides targeted coverage for MRSA in severe systemic infections.

Linezolid Kabi may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring during therapy. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Anemia: reduced red blood cell levels. - Peripheral neuropathy: numbness or tingling in extremities. - Serotonin syndrome: potentially life‑threatening when combined with serotonergic agents. - Lactic acidosis: metabolic disturbance with elevated lactate. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

When using Linezolid Kabi, consider the following precautions.

- Renal impairment: dose adjustment may be required and renal function should be monitored. - Hepatic impairment: monitor liver enzymes as metabolism may be affected. - Serotonergic agents: avoid concomitant use due to risk of serotonin syndrome. - Myelosuppression: regular complete blood count monitoring is advised. - Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from light and moisture.

Linezolid Kabi interacts with several drug classes.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Rifampicin: reduces linezolid plasma concentrations, potentially decreasing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Anticonvulsants (e.g., carbamazepine): may decrease linezolid levels, affecting therapeutic outcome. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk when combined with linezolid‑induced thrombocytopenia.